Uncategorized

RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the completion of enrollment in the Phase 1b portion of the ACTION-1 Phase 1b/3 trial of RYZ101 in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have progressed on Lutetium-177 labelled somatostatin analogue therapy.

Rubedo Life Sciences presented to key opinion leaders in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases.

The new PerkinElmer business acquired by New Mountain Capital announced today the appointment of Dirk Bontridder as Chief Executive Officer effective March 13, 2023.

Synchron today announced the COMMAND trial is commencing at Gates Vascular Institute, a Kaleida Health facility in Buffalo, N.Y. and teaching affiliate of the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB).

Sangamo Therapeutics lost two powerhouse partners Friday after it reported that both Novartis and Biogen discontinued focusing on gene regulation therapies in the neurology space.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).

Dante Genomics , a global leader in genomics and precision medicine, launched today the beta version of Avanti, the Company’s proprietary B2B software for variant interpretation and report writing at scale.

Karuna Therapeutics, Inc. announced positive topline results from its Phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT in adults with schizophrenia.

Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that its partner, Athenex Pharmaceutical Division, has just started to commercialize its abbreviated new drug application approval from the U.S. Food and Drug Administration for its Generic Version of Magnesium Sulfate in Water for Injection, 2 g/50 mL, 4 g/100 mL and 4 g/50

Syft Technologies announced the release of its next generation Selected Ion Flow Tube Mass Spectrometry technology, Syft Tracer™, at Pittcon 2023.